Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beta Bionics (BBNX) Shares Outstanding (Weighted Average) (2023 - 2025)

Beta Bionics' Shares Outstanding (Weighted Average) history spans 3 years, with the latest figure at $40.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 536.74% year-over-year to $40.5 million; the TTM value through Dec 2025 reached $40.5 million, up 536.74%, while the annual FY2025 figure was $40.5 million, 536.74% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $40.5 million at Beta Bionics, up from $39.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $43.4 million in Q2 2025 and bottomed at $5.3 million in Q4 2023.
  • The 3-year median for Shares Outstanding (Weighted Average) is $6.7 million (2024), against an average of $20.5 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) grew 20.01% in 2024 before it skyrocketed 615.56% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $5.3 million in 2023, then rose by 20.01% to $6.4 million in 2024, then surged by 536.74% to $40.5 million in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Shares Outstanding (Weighted Average) are $40.5 million (Q4 2025), $39.3 million (Q3 2025), and $43.4 million (Q2 2025).